Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing

NORTH PALM BEACH, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology company developing monoclonal antibodies targeting various cancer types, today announced that it has received a written notification from the OTC Markets Group as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) in a timely fashion. The Notification Letter advised ...